Article Menu
Need Help?
No Article Versions Notes Found
Cite
Malone, D.C.; Dean, R.; Arjunji, R.; Jensen, I.; Cyr, P.; Miller, B.; Maru, B.; Sproule, D.M.; Feltner, D.E.; Dabbous, O. Cost-Effectiveness Analysis of Using Onasemnogene Abeparvocec (AVXS-101) in Spinal Muscular Atrophy Type 1 Patients. J. Mark. Access Health Policy 2019, 7, 1601484. https://doi.org/10.1080/20016689.2019.1601484
Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-Effectiveness Analysis of Using Onasemnogene Abeparvocec (AVXS-101) in Spinal Muscular Atrophy Type 1 Patients. Journal of Market Access & Health Policy. 2019; 7(1):1601484. https://doi.org/10.1080/20016689.2019.1601484
Chicago/Turabian StyleMalone, Daniel C., Rebecca Dean, Ramesh Arjunji, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, and Omar Dabbous. 2019. "Cost-Effectiveness Analysis of Using Onasemnogene Abeparvocec (AVXS-101) in Spinal Muscular Atrophy Type 1 Patients" Journal of Market Access & Health Policy 7, no. 1: 1601484. https://doi.org/10.1080/20016689.2019.1601484
APA StyleMalone, D. C., Dean, R., Arjunji, R., Jensen, I., Cyr, P., Miller, B., Maru, B., Sproule, D. M., Feltner, D. E., & Dabbous, O. (2019). Cost-Effectiveness Analysis of Using Onasemnogene Abeparvocec (AVXS-101) in Spinal Muscular Atrophy Type 1 Patients. Journal of Market Access & Health Policy, 7(1), 1601484. https://doi.org/10.1080/20016689.2019.1601484
